Novel Adeno-Associated Virus Serotypes Efficiently Transduce Murine Photoreceptors
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Severe inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis, are caused by mutations in genes preferentially expressed in photoreceptors. While adeno-associated virus (AAV)-mediated gene transfer can correct retinal pigment epithelium (RPE) defects in animal models, approaches for the correction of photoreceptor-specific diseases are less efficient. We evaluated the ability of novel AAV serotypes (AAV2/7, AAV2/8, AAV2/9, AAV2rh.43, AAV2rh.64R1, and AAV2hu.29R) in combination with constitutive or photoreceptor-specific promoters to improve photoreceptor transduction, a limiting step in photoreceptor rescue. Based on a qualitative analysis, all AAV serotypes tested efficiently transduce the RPE as well as rod and cone photoreceptors after subretinal administration in mice. Interestingly, AAV2/9 efficiently transduces Müller cells. To compare photoreceptor transduction from different AAVs and promoters in both a qualitative and quantitative manner, we designed a strategy based on the use of a bicistronic construct expressing both enhanced green fluorescent protein and luciferase. We found that AAV2/8 and AAV2/7 mediate six- to eightfold higher levels of in vivo photoreceptor transduction than AAV2/5, considered so far the most efficient AAV serotype for photoreceptor targeting. In addition, following subretinal administration of AAV, the rhodopsin promoter allows significantly higher levels of photoreceptor expression than the other ubiquitous or photoreceptor-specific promoters tested. Finally, we show that AAV2/7, AAV2/8, and AAV2/9 outperform AAV2/5 following ex vivo transduction of retinal progenitor cells differentiated into photoreceptors. We conclude that AAV2/7 or AAV2/8 and the rhodopsin promoter provide the highest levels of photoreceptor transduction both in and ex vivo and that this may overcome the limitation to therapeutic success observed so far in models of inherited severe photoreceptor diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RPE cells can be targeted using AAV1, AAV4, or AAV6 vectors or with the engineered AAV2-7m8 vector, and photoreceptors and Müller glial cells are targeted by serotypes AAV2, AAV5, AAV6, AAV7, AAV8, and AAV9 as well as engineered AAV2-7m8 and AAV8BP2 vectors.56,112–116”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [114]
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“To evaluate the tropism of novel AAV serotypes following subretinal delivery to the adult murine retina and to determine if one is selective for photoreceptors, we generated AAV2/7 (25), AAV2/8 (25), AAV2/9 (23), AAV2/rh.”
MethodSelf-citationGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Retinal Stem Cells in the Adult Mammalian Eye
Tropepe, V., Coles, B. L. K., Chiasson, B. J., Horsford, D. J., Elia, A. J., McInnes, R. R., & van der Kooy, D. (2000) · Science · doi:10.1126/science.287.5460.2032 · Cited by 1,081 · cited 1×
“This limitation hampers the possibility of genetically modifying retinal stem cells derived from the adult eye (54), which can be used as tools for cell therapy of retinal degenerations.”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 6×
“64 (23) and was optimized for production by”
BackgroundMethodInfluentialSelf-citationRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762 · cited 1×
“others have demonstrated that it is possible to tailor somatic transgene expression on distinct retinal cell types in the adult and fetal retina by exchanging the AAV capsids among the various AAV serotypes and that this may impact the therapeutic outcome in animal models of retinal diseases (7, 44, 51, 57).”
BackgroundNew recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Self-citationHermonat, P. L., & Muzyczka, N. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.20.6466 · Cited by 481 · cited 1×
“Since the generation of the first AAV vector (30, 53) (AAV2/2, in which the first number defines the vector genome and the second the capsid), dozens of AAV variants have been isolated, and some of them have been converted into gene delivery vehicles (11, 12, 23–25, 45).”
BackgroundAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Rutledge, E. A., Halbert, C. L., & Russell, D. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.309-319.1998 · Cited by 452
Research works printed but not linked: 3
- Dryja, T. 2001. Retinitis pigmentosa and stationary night blindness, p.5903 -5933. In C. R. Scriver, A. L. Beaudet, W. Sly, and D. M. Valle (ed.), The metabolic and molecular bases of inherited disease, 8th ed.,vol. IV. McGraw-Hill, New York, NY.
- Gregory-Evans, K., and R. G. Weleber. 2001. Retinitis pigmentosa and allied disorders in retina, p.362-460. In S. J. Ryan (ed.), Retinavol. 1, 3rd ed. Mosby, St. Louis, MO.
- 10.1128/mcb.4.10.2072-2081.1984 · doi:10.1128/mcb.4.10.2072-2081.1984 · Paper page
Cited by
Items 101–200 of 245
Zhong, X., Hu, H., Shen, J., Zacchigna, S., Zentilin, L., Giacca, M., & Vinores, S. A. (2011) · PubMed Central · Cited by 47
Han, Z., Conley, S. M., & Naash, M. I. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6916 · Cited by 40
Present Molecular Limitations of ON-Bipolar Cell Targeted Gene Therapy
van Wyk, M., Hulliger, E. C., Girod, L., Ebneter, A., & Kleinlogel, S. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00161 · Cited by 43
“Auricchio) (Allocca et al., 2007) that was cut with BamHI and NheI (BamHI and BglII have compatible overhangs) to create the pAAV-4xGRM6-SV40 plasmid.”
BackgroundMethodGene Editing Preserves Visual Functions in a Mouse Model of Retinal Degeneration
Vagni, P., Perlini, L. E., Chenais, N. A. L., Marchetti, T., Parrini, M., Contestabile, A., Cancedda, L., & Ghezzi, D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00945 · Cited by 46
“, 2009), the posterior segment of the eye, especially the photoreceptors, can be efficiently transduced only by adeno associated viruses (AAVs) (Allocca et al., 2007).”
BackgroundRationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain
Sullivan, J. A., Stanek, L. M., Lukason, M. J., Bu, J., Osmond, S. R., Barry, E. A., O’Riordan, C. R., Shihabuddin, L. S., Cheng, S. H., & Scaria, A. (2018) · Gene Therapy · doi:10.1038/s41434-018-0017-8 · Cited by 37
Adeno-Associated Virus Mediated Gene Therapy for Retinal Degenerative Diseases
Stieger, K., Cronin, T., Bennett, J., & Rolling, F. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_8 · Cited by 35
AAV-PHP.eB transduces both the inner and outer retina with high efficacy in mice
Palfi, A., Chadderton, N., Millington‐Ward, S., Post, I. J. M., Humphries, P., Kenna, P. F., & Farrar, G. J. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.016 · Cited by 37
“The AAV2/8 serotype was chosen as a control as this serotype is known to transduce both rod and cone photoreceptors and RPE cells highly efficiently.(10,20,45,46) Robust EGFP expression in the photoreceptor layer”
BackgroundOccelli, L. M., Schön, C., Seeliger, M. W., Biel, M., Michalakis, S., & Petersen‐Jones, S. M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.155 · Cited by 37
“The expression cassette consisted of a 0.8 kb rod photoreceptor-specific human rhodopsin (hRHO) promoter, 28 and the full-length (2.58 kb) human PDE6A cDNA, which was amplified from human retinal cDNA with the following primers: forward 5 ¢ -AAAGCGGCCGC CACCATGGGCGAGGTGACAGCAG-3 ¢ and reverse 5 ¢…”
InfluentialMyosin7a Deficiency Results in Reduced Retinal Activity Which Is Improved by Gene Therapy
Colella, P., Sommella, A., Marrocco, E., Di Vicino, U., Polishchuk, E., Garrido, M. G., Seeliger, M. W., Polishchuk, R., & Auricchio, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072027 · Cited by 34
“1-CMV-hMYO7A cis-plasmid that contains the complete human MYO7A (hMYO7A) coding sequence (6648 bp) under the control of the ubiquitous cytomegalovirus (CMV) promoter, which is active in both PRs and RPE [37,38].”
BackgroundMethodSelf-citationRibas, V. T., & Costa, M. R. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00231 · Cited by 34
“This, together with the route administration, allows the user to select the most appropriate AAV serotype to transduce the neuronal cell type of interest (Auricchio et al., 2001; Allocca et al., 2007; Lebherz et al., 2008; Hutson et al., 2012).”
BackgroundBlack, A., Vasireddy, V., Chung, D. C., Maguire, A. M., Gaddameedi, R., Tolmachova, T., Seabra, M., & Bennett, J. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2768 · Cited by 32
“Furthermore, AAV8 can be used at a ten-fold lower dose of AAV2 to achieve equivalent expression in the same set of cells [7,24,37].”
BackgroundChen, S.-J., Johnston, J., Sandhu, A., Bish, L. T., Hovhannisyan, R., Jno-Charles, O., Sweeney, H. L., & Wilson, J. M. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.129 · Cited by 32
“…Pleger et al., 2011; Prasad et al., 2011; Pulicherla et al., 2011), muscle (Kornegay et al., 2010; Sun et al., 2010; Pulicherla et al., 2011), eye (Allocca et al., 2007), spinal cord (Foust et al., 2009; Snyder et al., 2011), and CNS (Cearley et al., 2008; Foust et al., 2009; Fu et al., 2011;…”
BackgroundSelf-citationDa Costa, R., Röger, C., Segelken, J., Barben, M., Grimm, C., & Neidhardt, J. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19701 · Cited by 32
KIT ligand protects against both light-induced and genetic photoreceptor degeneration
Li, H., Lian, L., Liu, B., Chen, Y., Yang, J., Jian, S., Zhou, J., Xu, Y., Ma, X., Qu, J., et al. (2020) · eLife · doi:10.7554/elife.51698 · Cited by 32
“68 fold, n = 4) and IF (Figure 5G and H), confirming previous reports (Allocca et al., 2007).”
MethodResultDevelopment of gene therapy for treatment of age‐related macular degeneration
Askou, A. L. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12452 · Cited by 36
“This revealed efficient gene expression in RPE cells following subretinal delivery of 10(9) AAV2/8-CMV-eGFP particles, which is in agreement with other studies utilizing the AAV2/8 vector (Allocca et al. 2007; Natkunarajah et al. 2008).”
BackgroundMethodResultInfluentialGene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
Recombinant adeno-associated Virus: Clinical Application and Development As a gene-therapy Vector
Xiao, P.-J., Lentz, T. B., & Samulski, R. J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.63 · Cited by 32
Efficient mutagenesis of the rhodopsin gene in rod photoreceptor neurons in mice
Chan, F., Hauswirth, W. W., Wensel, T. G., & Wilson, J. H. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr196 · Cited by 34
“However, recent reports suggest that transduction efficiencies can be improved using other serotypes of AAV (39,40), an observation we have confirmed in our system (F.”
Self-citationDual AAV Vectors for Stargardt Disease
Trapani, I. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_11 · Cited by 33
Schön, C., Asteriti, S., Koch, S., Sothilingam, V., Garrido, M. G., Tanimoto, N., Herms, J. W., Seeliger, M. W., Cangiano, L., Biel, M., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv639 · Cited by 35
“The YFP sequence was fused with a glycine-serine-glycine linker to the N-terminus ofmouseHcn1 using overlap PCR (39) and ligatedwith the human rhodopsin promoter sequence (40) into pAAV2.”
MethodRecent Developments in Gene Therapy for Neovascular Age-Related Macular Degeneration: A Review
Finocchio, L., Zeppieri, M., Gabai, A., Toneatto, G., Spadea, L., & Salati, C. (2023) · Biomedicines · doi:10.3390/biomedicines11123221 · Cited by 34
“Gene therapy products utilizing AAV vector systems, including Glybera (alipogene tiparvovec to treat hereditary lipoprotein lipase deficiency) [122], Luxturna (voretigene neparvovec-rzyl), Zolgensma (onasemnogene abeparvovec to treat spinal muscular atrophy type 1) [123] and Hemgenix (Etranacogene…”
MethodCarrella, S., Guida, M. D., Brillante, S., Piccolo, D., Ciampi, L., Guadagnino, I., García‐Piqueras, J., Pizzo, M., Marrocco, E., Molinari, M., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215941 · Cited by 28
Self-citationDemontis, G. C., Aruta, C., Comitato, A., Marzo, A. D., & Marigo, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033338 · Cited by 26
“Cells were infected at D4 with an AAV2/8 expressing EGFP under the control of the rhodopsin promoter (AAV2/8-pRho-EGFP) (1610(6) GC/cell) according to the procedure described in [15].”
MethodSelf-citationTornabene, P., Trapani, I., Centrulo, M., Marrocco, E., Minopoli, R., Lupo, M., Iodice, C., Gesualdo, C., Simonelli, F., Surace, E. M., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.004 · Cited by 25
“AAV8 vectors were used because of their high efficiency of photoreceptor transduction.(39)”
MethodSelf-citationGaroon, R. B., & Stout, J. T. (2016) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000256 · Cited by 25
Yan, Z., Yao, Y., Li, L., Cai, L., Zhang, H., Zhang, S., Xiao, Q., Wang, X., Zuo, E., Xu, C., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.08.002 · Cited by 28
AAV Vectors for FRET-Based Analysis of Protein-Protein Interactions in Photoreceptor Outer Segments
Bećirović, E., Böhm, S., Nguyen, O. N. P., Riedmayr, L. M., Hammelmann, V., Schön, C., Butz, E. S., Wahl‐Schott, C., Biel, M., & Michalakis, S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00356 · Cited by 29
Petit, L., Ma, S., Cheng, S.-Y., Gao, G., & Punzo, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.020 · Cited by 24
“In particular, injection of AAV2/8 at postnatal day (PND) 0 results primarily in cone transduction (*100% of cones, almost no rods), whereas the vast majority of transduced cells in adults are rods.(14,15,32) The current study took advantage of this shift in tropism to identify host factors critical for AAVmediated PR…”
Zhong, H., Eblimit, A., Moayedi, Y., Boye, S. L., Chiodo, V. A., Chen, Y., Li, Y., Nichols, R. M., Hauswirth, W. W., Chen, R., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.42 · Cited by 26
Adeno-associated virus serotype-9 efficiently transduces the retinal outer plexiform layer.
Lei, B., Zhang, K., Yue, Y., Ghosh, A., & Duan, D. (2009) · PubMed Central · Cited by 28
Channelrhodopsins provide a breakthrough insight into strategies for curing blindness
Tomita, H., Sugano, E., Isago, H., & Tamai, M. (2009) · Journal of Genetics · doi:10.1007/s12041-009-0062-6 · Cited by 27
“Photoreceptor & RPE in mice Allocca et al. (2007)”
Park, S. W., Kim, J. H., Park, W. J., & Kim, J. H. (2015) · Journal of Visualized Experiments · doi:10.3791/53030 · Cited by 26
Marginal integrity of self- and total-etching adhesives in two different application protocols.
Ernsta, C.-P., Kötter, T., Victor, A., Canbek, K., Brandenbusch, M., & Willershausen, B. (2004) · PubMed · Cited by 31
Keswani, S. G., Balaji, S., Le, L. D., Leung, A., Lim, F. Y., Habli, M. A., Jones, H. N., Wilson, J. M., & Crombleholme, T. M. (2012) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2012.00810.x · Cited by 26
“Gene transfer with more durable transgene expression has been reported in a variety of tissues including brain, retina, liver, lung, and muscle, using lentiviral and adeno-associated virus (AAV)-based vectors (5-7).”
BackgroundSelf-citationMutation-independent rescue of a novel mouse model of Retinitis Pigmentosa
Greenwald, D. L., Cashman, S. M., & Kumar‐Singh, R. (2012) · Gene Therapy · doi:10.1038/gt.2012.53 · Cited by 26
Schön, C., Sothilingam, V., Mühlfriedel, R., Garrido, M. G., Beck, S. C., Tanimoto, N., Wissinger, B., Paquet‐Durand, F., Biel, M., Michalakis, S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.156 · Cited by 23
Efficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho−/− mouse
Palfi, A., Chadderton, N., O’Reilly, M., Nagel‐Wolfrum, K., Wolfrum, U., Bennett, J., Humphries, P., Kenna, P. F., Millington‐Ward, S., & Farrar, J. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.16 · Cited by 24
The Future of Nanomaterials Tackling the Challenge of Delivering Nucleic Acids to the Retina
Hurst, J., Adams, F., & Schnichels, S. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202407173 · Cited by 24
Ocular gene therapy for choroideremia: clinical trials and future perspectives
Xue, K., & MacLaren, R. E. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1475232 · Cited by 24
Bernardo‐Colón, A., Bighinati, A., Parween, S., Debnath, S., Piano, I., Adani, E., Corsi, F., Gargini, C., Vergara, M. N., Marigo, V., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00789-8 · Cited by 24
“The AAV-H105A and AAV-GFP, as control, viruses were generated by InnovaVector (Poz-zuoli, NA, Italy) 39 .”
Self-citationAdeno-associated virus vectors for retinal gene therapy in basic research and clinical studies
Xia, X., & Guo, X. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1310050 · Cited by 25
“In basic research, subretinal injection of AAV2/1 and AAV2/9 was able to efficiently transduce Müller glial cells in adult mice (33, 40, 57) (Figure 2D).”
BackgroundPrea, S. M., Chan, E. C., Dusting, G. J., Vingrys, A. J., Bui, B. V., & Liu, G. (2015) · Journal of Ophthalmology · doi:10.1155/2015/201726 · Cited by 25
“Whereas rAAV2/4 produces gene expression limited to the RPE [67], rAAV2/7 and rAAV2/8 show promising transduction of photoreceptor cells [70].”
High-throughput Screening and Biophysical Interrogation of Hepatotropic AAV
Murphy, S. L., Bhagwat, A., Edmonson, S., Zhou, S., & High, K. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.210 · Cited by 20
Pradhan, A. D., Case, A. M., Farrer, R. G., Tsai, S.-Y., Cheatwood, J. L., Martin, J. W., & Kartje, G. L. (2010) · Developmental Neuroscience · doi:10.1159/000309135 · Cited by 22
Sahu, B., Leon, L. M., Zhang, W., Puranik, N., Periasamy, R., Khanna, H., & Volkert, M. R. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.12.8 · Cited by 23
Antiangiogenic Eye Gene Therapy
Corydon, T. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.064 · Cited by 21
Kay, C. N., Ryals, R. C., Aslanidi, G., Min, S.-H., Ruan, Q., Sun, J., Dyka, F. M., Kasuga, D. T., Ayala, A. E., Vliet, K. V., et al. (2013) · PLoS ONE · doi:10.1371/annotation/99ee1789-a658-4fb0-8593-40a40e9f344a · Cited by 18
Song, H., Bush, R. A., Zeng, Y., Qian, H., Wu, Z., & Sieving, P. A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.006 · Cited by 17
Hughes, C., O’Flynn, N. M. J., Gatherer, M., McClements, M. E., Scott, J. A., MacLaren, R. E., Goverdhan, S. V., Glennie, M. J., & Lotery, A. J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.005 · Cited by 17
Treatment Potential for LCA5 -Associated Leber Congenital Amaurosis
Uyhazi, K. E., Aravand, P., Bell, B. A., Wei, Z., Leo, L., Serrano, L. W., Pearson, D. J., Shpylchak, I., Pham, J., Vasireddy, V., et al. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.5.30 · Cited by 18
Correction: AAV9 Targets Cone Photoreceptors in the Nonhuman Primate Retina
Vandenberghe, L. H., Bell, P., Maguire, A. M., Xiao, R., Hopkins, T. B., Grant, R., Bennett, J., & Wilson, J. M. (2013) · PLoS ONE · doi:10.1371/annotation/64b90996-4634-4c63-b737-634397b0b445 · Cited by 16
Self-citationGene-agnostic approaches to treating inherited retinal degenerations
Chew, L. A., & Iannaccone, A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1177838 · Cited by 17
“For this reason, promoters with activity restricted to specific cell types (such as human rhodopsin (Allocca et al., 2007; Busskamp et al., 2010) [rods], cone arrestin [cones] (Zhu et al.”
BackgroundRetinal gene therapy: current progress and future prospects
Ku, C. A., & Pennesi, M. E. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1035711 · Cited by 18
“Note that information pertaining to transduction efficiencies is representative of murine retina [39,43], but variances between species have been reported [151].”
BackgroundMaddalena, A., Dell'Aquila, F., Giovannelli, P., Tiberi, P., Wanderlingh, L. G., Montefusco, S., Tornabene, P., Iodice, C., Visconte, F., Carissimo, A., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.220 · Cited by 16
Self-citationPuppo, A., Bello, A., Manfredi, A., Cesi, G., Marrocco, E., Corte, M. D., Rossi, S., Giunti, M., Bacci, M. L., Simonelli, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059025 · Cited by 18
“AAV2/8 is considered the current gold standard for PR transduction across several species [19-20,22,53].”
BackgroundSelf-citationLei, B., Zhang, K., Yue, Y., Ghosh, A., & Duan, D. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1399-9_77 · Cited by 16
“Both studies demonstrated efficient transduction of the RPE andMüller cells (Allocca et al. 2007; Lebherz et al. 2008).”
BackgroundResultInfluentialHori, T., Fukutome, M., & Koike, C. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00913 · Cited by 16
Morpho‐Rheological Fingerprinting of Rod Photoreceptors Using Real‐Time Deformability Cytometry
Santos‐Ferreira, T., Herbig, M., Otto, O., Carido, M., Karl, M., Michalakis, S., Guck, J. R., & Ader, M. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23798 · Cited by 15
“1-ss-RHO-eGFP-WPRE cis plasmid was used to produce single-strand AAV8Y733F-pseudotyped AAV2 vectors (48) expressing eGFP under control of a human rhodopsin (RHO) promoter (49).”
MethodOverview of Retinal Gene Therapy: Current Status and Future Challenges
Bennett, J. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041278 · Cited by 15
Wagner, J. E., Zobel, L., Gerhardt, M. J., O’Riordan, C. R., Frederick, A., Petersen‐Jones, S. M., Biel, M., & Michalakis, S. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.121 · Cited by 15
Baba, Y., Satoh, S., Otsu, M., Sasaki, E., Okada, T., & Watanabe, S. (2012) · Biochimie · doi:10.1016/j.biochi.2012.08.010 · Cited by 16
AAVrh-10 transduces outer retinal cells in rodents and rabbits following intravitreal administration
Zeng, Y., Qian, H., Wu, Z., Marangoni, D., Sieving, P. A., & Bush, R. A. (2019) · Gene Therapy · doi:10.1038/s41434-019-0094-3 · Cited by 12
Challenges in AAV-Based Retinal Gene Therapies and the Role of Magnetic Nanoparticle Platforms
Siontas, O., & Ahn, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237385 · Cited by 13
“Rod-specific expression relies on rhodopsin promoters from different species [48,49].”
A review of the 661W cell line as a tool to facilitate treatment development for retinal diseases
Brunet, A. A., James, R. E., Swanson, P., & Carvalho, L. S. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01381-2 · Cited by 13
Adeno-Associated Virus-Mediated Gene Therapy
Zaman, H., Khan, A. U., Khan, K., Toheed, S., Abdullah, M., Zeeshan, H. M., Hameed, A., Umar, M., Shahid, M., Malik, K. A., et al. (2023) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2023048135 · Cited by 12
Gene Therapy for Retinal Dystrophies: Twenty Years in the Making
Ali, R. R. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.2506 · Cited by 12
“Subretinal administration of AAV vectors, especially those derived from AAV serotypes 5 and 8, has been shown to lead to highly efficient photoreceptor cell transduction (Allocca et al. , 2007) and prolonged, potentially life-long, expression of the transgene.”
Shining light on CRISPR/Cas9 therapeutics for inherited retinal diseases
Geiger, A., Kennedy, J. G., Staker, L. G., Wensel, T. G., Casson, R. J., & Thomas, P. Q. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101376 · Cited by 11
Gene delivery to cone photoreceptors by subretinal injection of rAAV2/6 in the mouse retina
Hori, T., Fukutome, M., Maejima, C., Matsushima, H., Kobayashi, K., Kitazawa, S., Kitahara, R., Kitano, K., Kobayashi, K., Moritoh, S., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.117 · Cited by 12
Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy
Simna, S. P., & Han, Z. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210419090357 · Cited by 11
La conception de vecteurs adaptés à la thérapie génique oculaire
Khabou, H., & Dalkara, D. (2015) · médecine/sciences · doi:10.1051/medsci/20153105015 · Cited by 17
“Ces virus infectent la rétine neurale ainsi que l’épithélium rétinien pigmentaire, indépendamment de l’âge chez le rongeur [21, 22], et ils ont été utilisés avec succès chez l’homme [23, 24].”
Swirski, S., May, O., Ahlers, M. T., Wissinger, B., Greschner, M., Jüschke, C., & Neidhardt, J. (2023) · Cells · doi:10.3390/cells12060955 · Cited by 11
“These observations are in line with previously published data of transduction efficacies of the AAV2/8 serotype [38,42,43].”
ResultFighting Blindness with Adeno-Associated Virus Serotype 8
Auricchio, A. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.2521 · Cited by 11
Self-citationXiong, W., & Cepko, C. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-17121-0_67 · Cited by 9
Toutounchian, S., Ahmadbeigi, N., & Mansouri, V. (2022) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2022.0022 · Cited by 10
“132,133 One of the main limitations of AAV gene therapy is the potential immune response to the AAV capsid, which may reduce therapeutic effects and also could have possible deleterious effects.”
Minella, A., Mowat, F. M., Willett, K. L., Sledge, D. G., Bartoe, J. T., Bennett, J., & Petersen‐Jones, S. M. (2014) · Gene Therapy · doi:10.1038/gt.2014.65 · Cited by 9
Stem cell transplantation as a progressing treatment for retinitis pigmentosa
Shabanan, S. H., Seyedmirzaei, H., Barnea-Cramer, A. O., Hanaei, S., & Rezaei, N. (2022) · Cell and Tissue Research · doi:10.1007/s00441-021-03551-3 · Cited by 11
“In terms of AAV2, the most studied subgroup, these vectors act in a serotype-dependent manner, as AAV2/7 and AAV2/8 serotypes transduced higher levels of photoreceptors, and there are reports on effectiveness of AAV2/5 as well (Allocca et al. 2007).”
BackgroundMassengill, M. T., Young, B. M., Lewin, A. S., & Ildefonso, C. J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9065-8_15 · Cited by 9
Genersatztherapie bei genetisch bedingter Zapfenblindheit
Mühlfriedel, R., Tanimoto, N., & Seeliger, M. W. (2014) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0034-1368180 · Cited by 8
Vendomèle, J., Chauveau, G. A., Dalkara, D., Galy, A., & Fisson, S. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.191 · Cited by 6
Reichel, F. F., Fischer, M. D., Štingl, K., Kuehlewein, L., Seitz, I. P., Peters, T. M., Ziegler, M., Wilhelm, B., Kohl, S., Weisschuh, N., et al. (2025) · British Journal of Ophthalmology · doi:10.1136/bjo-2024-326480 · Cited by 6
“17 More details can be found in the online supplemental eAppendix and the study protocol.”
Onishi, A., Tsunekawa, Y., Mandai, M., Ishimaru, A., Ohigashi, Y., Sho, J., Yasuda, K., Suzuki, K., Belmonte, J. C. I., Matsuzaki, F., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.13.38 · Cited by 6
“20,27 First, we packaged the HITI gene constructs into two AAV8 vectors, in which the donor and U6-gRNA1 cassettes were integrated into a single AAV8, according to a previous HITI study 20 (Supplementary Fig.”
Mason, J. B., Gurda, B. L., Engiles, J. B., Hankenson, K. D., Wilson, J. M., & Richardson, D. W. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.199 · Cited by 6
“Serotypes rAAV2/8 and 2/9 have enhanced in vivo transduction properties in our laboratories despite their lackluster in vitro performance (Allocca et al., 2007; Keswani et al., 2012; Mason et al., 2012).”
BackgroundSelf-citationA 350 bp region of the proximal promoter of Rds drives cell-type specific gene expression
Cai, X., Conley, S. M., Cheng, T., Al‐Ubaidi, M. R., & Naash, M. I. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.04.017 · Cited by 9
“macular dystrophy 2 (VMD2) and rhodopsin (MOP) and ubiquitously expressed promoters like chicken beta-actin (CBA) have been successfully used to direct expression in the retina (Allocca et al., 2007; Cai et al., 2009a, 2009b), strong promoters that can direct proper levels of gene expression in rods and cones have bee…”
BackgroundPonder, K. P., & Auricchio, A. (2010) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2010.02367.x · Cited by 6
“ubiquitous) could enhance cell-specific expression.(25)”
BackgroundSelf-citationManufacturing Considerations and Challenges for AAV Ocular Gene Therapy
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Rivers, H. M., Feng, S., Shah, D., & Slater, N. K. H. (2021) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-76367-1_22 · Cited by 5
Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities
Belova, L., Лавров, А. В., & Smirnikhina, S. (2022) · BioEssays · doi:10.1002/bies.202200055 · Cited by 6
“This explains the high efficiency of transduction of retinal organs with serotype 9 rAAV vectors in studies on animal models in vivo,[108,109] but at the same time the low efficiency of transduction of retinal organoids.”
BackgroundThe role ofcis-regulatory elements in the design of gene therapy vectors for inherited blindness
Corbo, J. C. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.5.599 · Cited by 6
Challenging Safety and Efficacy of Retinal Gene Therapies by Retinogenesis
Marrocco, E., Maritato, R., Botta, S., Esposito, M., & Surace, E. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115767 · Cited by 6
“(F) Representative ERG track responses in scotopic and photopic conditions in one-month old P347S adRP mice treated with AAV8-CMV-ZF6-DB at postnatal day 4 and P14 compared with sham injected contralateral controls eyes.”
MethodSelf-citationSchön, C., Bećirović, E., Biel, M., & Michalakis, S. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_3 · Cited by 6
Gene therapy shines light on congenital stationary night blindness for future cures
Zhang, Y., Lin, S., Yu, L., Lin, X. Y., Qu, S., Ye, Q., Yu, M., Chen, W., & Wu, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06392-8 · Cited by 5
“In their experiments, they utilized rAAV RHO:: Lrit3 , which carries the human rhodopsin promoter (RHO) to drive the expression of the Lrit3 in photoreceptors [194].”
Gene Therapy for Retinitis Pigmentosa
Tomita, H., Sugano, E., Isago, H., Murayama, N., & Tamai, M. (2013) · InTech eBooks · doi:10.5772/52987 · Cited by 5
“of the retina via intravitreous injection of AAV vectors, in spite of the development of various serotypes of AAV vectors for retinal gene therapy [61-65].”
BackgroundKelley, R. A., & Wu, Z. (2023) · Vision Research · doi:10.1016/j.visres.2023.108269 · Cited by 5
Joussemet, B., Belbellaa, B., Mendes-Madeira, A., Bucher, T., Briot, D., Dubreil, L., Colle, M.-A., Chérel, Y., Moullier, P., & Rolling, F. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.06.012 · Cited by 5
Gene therapy to treat inherited and complex retinal degenerative diseases
Rex, T. S. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.27 · Cited by 5
Gene Therapy for Retinal Diseases
Gopinath, C., Sarkar, S., & Ghosh, A. (2021) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-15-9184-6_30 · Cited by 3
Expression Cassette Design and Regulation of Transgene Expression
Keravala, A., & Gasmi, M. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000363 · Cited by 5
Molecular Therapy for Choroideremia: Pre-clinical and Clinical Progress to Date
Kalatzis, V., Roux, A., & Meunier, I. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00558-y · Cited by 5
Recombinant Adeno-Associated Virus Serotype 6 Efficiently Transduces Primary Human Melanocytes
Sheppard, H. M., Ussher, J. E., Verdon, D. J., Chen, J. H., Taylor, J. A., & Dunbar, P. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062753 · Cited by 4
“Interestingly, retinal pigment epithelium, the other pigmented cell type in the eye, can also be transduced by rAAV but rAAV6 is less efficient than other serotypes [39,40,41,42], highlighting the need to determine the optimal serotype for each cell type experimentally.”
BackgroundElectroporation in the Rodent Retina In Vivo and In Vitro
Matsuda, T. (2015) · Neuromethods · doi:10.1007/978-1-4939-2459-2_4 · Cited by 3
Duarte, F. T., & Arsenijévic, Y. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101424 · Cited by 2
Metadata
- Authors
- Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L. H., Wilson, J. M., Marigo, V., Surace, E. M., & Auricchio, A.
- Affiliations
- European School of Molecular Medicine (IT)
- Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy
- University of Modena and Reggio Emilia (IT)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Pennsylvania (US)
- Federico II University Hospital (IT)
- ORCID
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2007-10-15
- Volume
- 81
- Issue
- 20
- Pages
- 11372-11380
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC2045569
- OpenAlex
- W2155190242
- Cited by
- 246
- References
- 59
- Citations by year
- 2026: 11 · 2025: 9 · 2024: 6 · 2023: 10 · 2022: 11 · 2021: 14 · 2020: 10 · 2019: 14 · 2018: 12 · 2017: 16 · 2016: 7 · 2015: 30 · 2014: 11 · 2013: 16 · 2012: 13
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Funders
- National Eye Institute (R01EY015136)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus serotypes, phototransduction, AAV2/8, AAV2/9, rhodopsin promoter, retinitis pigmentosa, Leber congenital amaurosis, inherited retinal disease, subretinal gene therapy, Müller cells, retinal progenitor cells, AAV2/5, luciferase reporter
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Photoreceptor Cells, Promoter Regions, Genetic, Retina, Rhodopsin, Serotyping, Transduction, Genetic, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.